Abstract 1981
Background
Thanks to the new therapeutic strategies, the patients with MM live longer, but with complex chronic disease and with a diversity of supportive treatments that are increasingly complex. The bisphosphonates are important part of these therapeutic options for them. The aim of this study is to describe four clinical cases presenting dental complications and to define the prevention actions they needed.
Methods
A series of cases study. Sample 4 cases with MM patients in treatment with bisphosphonates attended by Functional Unit during 6 months in 2018. Variables recruited were dental complications, nurses’ activities, clinical implications and type of treatment received.
Results
From October-2018 to March-2019, a total of 32 patients with MM have been received intravenous bisphosphonates treatment. Four of them (12.5%) have presented dental complications that are following: Two patients (♂ 68 years old and ♀ 68) have needed a 6 months of bisphosphonates interruption to have a dental extraction One patient (♂ 51 years) has delayed 15 days his autologous stem cell transplantation due to dental extraction with infection One patient (♂ 69 years) has delayed one month his autologous stem cell because of a dental fistula that needed surgical intervention Preventive nurses’ measures included: dental assessment prior to bisphosphonate initiation so that any invasive dental procedures could be completed prior to initiation the therapy. It is crucial to include prevention in the health system to avoid increasing financial toxicity for patients & families.
Conclusions
All the patients with dental complications affected and delayed the planned treatment. A preventive approach with oral care before and during treatment with bisphosphonates can minimize the occurrence of complications associated with treatment and avoid interruptions since extractions are contraindicated and endodontic treatment should be performed under conditions that ensure no trauma to bone tissue. Nurses should be aware that MM patient treatment depends not only on anti-myeloma treatments but, also on supportive measures to improve their quality of life and avoid complications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cesca Llopis.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1121 - Experiences of endocrine therapy after breast cancer surgery
Presenter: Susanne Ahlstedt Karlsson
Session: Poster Display session 3
Resources:
Abstract
2305 - The effects of progressive muscle relaxation and mindfulness meditation on fatigue, coping styles, and quality of life in breast cancer patients receiving adjuvant paclitaxel regimen: An-assessor blinded, three-arm randomized controlled trial
Presenter: Zehra Gok Metin
Session: Poster Display session 3
Resources:
Abstract
4561 - Agreement between breast cancer patients and oncologists on the severity of patients’ symptoms and functions during a one-year follow-up after treatment.
Presenter: Randi Reidunsdatter
Session: Poster Display session 3
Resources:
Abstract
1768 - Taste Changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Gulcan Bagcivan
Session: Poster Display session 3
Resources:
Abstract
1830 - CART-19: a comparative between literature versus experience
Presenter: Cassandra Andersson Vila
Session: Poster Display session 3
Resources:
Abstract
4027 - Unplanned emergency department use by people receiving ambulatory anti-cancer agents with potential febrile neutropenia
Presenter: Meritxell Casanovas-Blanco
Session: Poster Display session 3
Resources:
Abstract
4754 - Examining the benefits of medical exercise during radiotherapy in patients after mastectomy
Presenter: Nikolina Dodlek
Session: Poster Display session 3
Resources:
Abstract
2510 - Assessment Quality of Life with Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in NSCLC
Presenter: Qi Jiang
Session: Poster Display session 3
Resources:
Abstract
2989 - Adverse effects of chemotherapy influence the patients’ quality of life : Analysis of implicated factors
Presenter: Maria Lavdaniti
Session: Poster Display session 3
Resources:
Abstract
3117 - A modified Edmonton Symptom Assessment Scale for assessing symptoms in one day chemotherapy clinic
Presenter: Anjuleta Kampitsi
Session: Poster Display session 3
Resources:
Abstract